Compare Dover Corp (DOV) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs McKesson Corporation — how do they compare? Dover Corp trades at $190.16 (market cap $25.45B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 4.3× Dover Corp's market cap, and Dover Corp pays the higher dividend (1.11%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and McKesson Corporation for 74 Days on average.
| DOV | MCK | |
|---|---|---|
Market Cap | $25.45B | $108.46B |
Volume | 661,758 | 712,607 |
Sector | Industrials | Health |
52-Week High | $233.31 | $995.69 |
52-Week Low | $161.16 | $725.17 |
Typical Hold Time | 73 Days | 74 Days |
Enterprise Value | $26.95B | $115.00B |
Dividend Yield | 1.11% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.29, down 1.87% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 13.48% net income margin and has beaten earnings expectations for three consecutive quarters. Recent acquisitions and product launches demonstrate ongoing business development. Analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.
The stock offers attractive upside based on analyst targets and consistent earnings performance, though technical indicators suggest near-term pressure. Key risks include market volatility and integration challenges from recent acquisitions. The company's Dividend King status and strong cash flow generation provide stability for long-term investors.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
